TO TORNTPHARM
Torrent Pharmaceuticals Q4 2026
TOTORNTPHARM

Torrent Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 22 May 2026

Management summary

  • Torrent Pharmaceuticals delivered a strong Q4 FY26, marked by robust consolidated revenue and EBITDA growth, largely driven by its India and Brazil businesses.
  • The successful launch of Semaglutide in India and the ongoing integration of JB Pharma are key highlights.
  • While some international markets faced headwinds, the company maintains a positive outlook with strategic product pipeline development and R&D focus.

Source: Inve concall analysis and management guidance record.

Highlights

  • Consolidated revenue for Q4 FY26 grew significantly by 42% to INR 4,197 crores.

  • Operating EBITDA for Q4 FY26 increased by 41% to INR 1,356 crores, maintaining a strong margin of 32.3%.

  • Torrent's base India business (ex-JB) grew 15% in Q4 FY26, outpacing the IPM growth of 10%.

  • The Curatio business grew 27% in FY26, driven by strong demand generation and field force expansion.

What they filed

Q4 FY26: revenue up 41.6%, net profit down 34.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue2,377 2,433 2,616 2,762 2,599 +9%3,445 +42%
EBITDA887 868 979 1,072 1,000 +13%1,228 +41%
Net profit485 474 551 597 577 +19%309 −35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Guidance & targets

Revenue

  • India Business Organic Growth Revenue · FY27 · Medium confidence mid-teens
  • Brazil Top-line Growth Revenue · 26-27 · Medium confidence 10-15%

Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.

Q&A highlights

2 direct
JB Pharma Synergy Phasing Direct
We had guided for up to INR450 crores synergies by year 3, and about 20% of that in year 1. It is difficult to quantify quarter-by-quarter because we implement something as an action, but the actual reflection of the saving may take some time and may vary. But our early sense is

Clarifies the timeline and magnitude of expected synergies from the JB Pharma acquisition and indicates positive early progress on margin trajectory.

Asked by Kunal Dhamesha

India Organic Growth Outlook for FY27 Direct
Yes, but we've also mentioned that this would be in absence of any external demand shocks which currently is unknown to everyone. So if there is no such situation, then yes, I think that would be realistic [for mid-teens growth].

Provides a specific growth target for the core India business but with an important caveat regarding macro demand shocks, highlighting a potential risk.

Asked by Rahul Jeewani

Unlock risks & concerns, Q1 FY27 watchlist, and full call analysis

You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:

  • 8 risks, concerns & management red flags
  • 5 watchlist triggers for Q1 FY27
  • +8 more guidance targets & verbatim management quotes
  • +6 more analyst Q&A exchanges & evasion checks
  • Capital allocation & full section-by-section narrative

Sign in to use your monthly call allowance.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image